We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adma Biologics (ADMA) Falls More Steeply Than Broader Market: What Investors Need to Know
Read MoreHide Full Article
In the latest close session, Adma Biologics (ADMA - Free Report) was down 1.01% at $9.36. The stock fell short of the S&P 500, which registered a loss of 0.59% for the day. Meanwhile, the Dow lost 0.6%, and the Nasdaq, a tech-heavy index, lost 0.65%.
Shares of the infectious disease drug developer witnessed a loss of 3.37% over the previous month, trailing the performance of the Medical sector with its loss of 0.36%, and the S&P 500's loss of 1.37%.
Market participants will be closely following the financial results of Adma Biologics in its upcoming release. On that day, Adma Biologics is projected to report earnings of $0.19 per share, which would represent year-over-year growth of 18.75%. At the same time, our most recent consensus estimate is projecting a revenue of $139.8 million, reflecting a 4.16% rise from the equivalent quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.78 per share and a revenue of $536.82 million, representing changes of +30% and +5.22%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Adma Biologics. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. As of now, Adma Biologics holds a Zacks Rank of #3 (Hold).
Digging into valuation, Adma Biologics currently has a Forward P/E ratio of 12.17. This expresses a discount compared to the average Forward P/E of 20.54 of its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 169, finds itself in the bottom 32% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Adma Biologics (ADMA) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest close session, Adma Biologics (ADMA - Free Report) was down 1.01% at $9.36. The stock fell short of the S&P 500, which registered a loss of 0.59% for the day. Meanwhile, the Dow lost 0.6%, and the Nasdaq, a tech-heavy index, lost 0.65%.
Shares of the infectious disease drug developer witnessed a loss of 3.37% over the previous month, trailing the performance of the Medical sector with its loss of 0.36%, and the S&P 500's loss of 1.37%.
Market participants will be closely following the financial results of Adma Biologics in its upcoming release. On that day, Adma Biologics is projected to report earnings of $0.19 per share, which would represent year-over-year growth of 18.75%. At the same time, our most recent consensus estimate is projecting a revenue of $139.8 million, reflecting a 4.16% rise from the equivalent quarter last year.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $0.78 per share and a revenue of $536.82 million, representing changes of +30% and +5.22%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Adma Biologics. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. As of now, Adma Biologics holds a Zacks Rank of #3 (Hold).
Digging into valuation, Adma Biologics currently has a Forward P/E ratio of 12.17. This expresses a discount compared to the average Forward P/E of 20.54 of its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 169, finds itself in the bottom 32% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.